A Polypill for Secondary Prevention of Ischemic Heart Disease

  • End date
    Aug 26, 2024
  • participants needed
  • sponsor
    Isfahan University of Medical Sciences
Updated on 26 January 2021
heart failure
heart disease
bypass graft
beta blockers
hmg-coa reductase inhibitor
ace inhibitor
acute coronary syndrome
secondary prevention
beta-adrenergic blocking agents
acute myocardial infarction
hmg-coa reductase inhibitors


Cardiovascular diseases (CVD) are the leading cause of mortality and morbidity worldwide. The most important aspect of CVD secondary prevention is adherence to guideline-indicated pharmacological therapy which globally remains low. In previous studies, a Polypill containing fixed dose combination of essential drugs have improved patient adherence to these drugs. The effect of such a strategy on pharmacological therapy uptake, cost-effectiveness, and CVD recurrence in our setting will be assessed in this study. Participants hospitalized in three referral hospitals in Isfahan, Iran because of an acute myocardial infarction (MI) (ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI)) will be randomized to either receiving Polypill or usual care after MI. Patient recruitment will be carried out at the time of patient discharge from the hospitals.

Condition Myocardial Infarction, Heart Attack (Myocardial Infarction), Heart Attack (Myocardial Infarction), STEMI, Acute Myocardial Infarction, Non-ST-elevation Myocardial Infarction, ST Elevation Myocardial Infarction
Treatment PolyPill
Clinical Study IdentifierNCT03541109
SponsorIsfahan University of Medical Sciences
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Patients hospitalized because of an acute myocardial infarction (STEMI/NSTEMI) and alive after discharge for at least 1 month
signing informed consent
clear indication of receiving all components of Polypill (aspirin, statin, ACE inhibitor/ARB, and beta blocker)
living in Isfahan city or nearby areas so that they can attend follow-ups
No mental illness limiting their self-care ability or Severe illness with an estimated lifespan of less than 3 years
No history of adverse reaction or contraindication to any component of the Polypill
Not having Secondary hyperlipidemia, serum creatinine 2, severe heart failure
No plan for a procedure (CABG, PCI, or another surgical procedures) within following 6 months

Exclusion Criteria

Patient unlikely to complete trial
Need to change or discontinue any of the four principal drugs of the Polypill to achieve better control of the disease or risk factors or because of adverse drug reactions (based on physician's idea)
Severe illness with an estimated lifespan of less than 3 years
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note